BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 30463802)

  • 1. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
    Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
    Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
    De Vreese R; D'hooghe M
    Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
    Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
    Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
    Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.
    Taddei M; Cini E; Giannotti L; Giannini G; Battistuzzi G; Vignola D; Vesci L; Cabri W
    Bioorg Med Chem Lett; 2014 Jan; 24(1):61-4. PubMed ID: 24345446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the first histone deacetylase 6/8 dual inhibitors.
    Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
    J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
    Kollar J; Frecer V
    J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
    Thaler F; Mercurio C
    ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzofused hydroxamic acids: useful fragments for the preparation of histone deacetylase inhibitors. Part 2: 7-fluorobenzothiophenes and benzofurans.
    Marastoni E; Bartoli S; Berettoni M; Cipollone A; Ettorre A; Fincham CI; Mauro S; Paris M; Porcelloni M; Bigioni M; Binaschi M; Nardelli F; Parlani M; Maggi CA; Paoli P; Rossi P; Fattori D
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1603-6. PubMed ID: 25746815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.